Company Overview
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.53% |
| 6 Months: | -98.24% |
| 3 Months: | -93.10% |
| 1 Month: | -81.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)19.56 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLXN Silexion Therapeutics Corp PHARMA | 0.34 | -0.02 | $1.89M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 1.65M | 2.28M | 3.29M | 4.41M | 2.75M |
| Operating Income | -1.41M | -731.00K | -1.25M | -1.39M | -8.04M | - | -1.65M | -2.28M | -3.29M | -4.41M | -2.75M |
| EBITDA | - | - | - | - | - | - | -1.72M | -2.50M | -3.25M | -4.40M | -2.75M |
| Interest Expense | - | - | - | - | - | - | 9.00K | 0 | 4.00K | 6.00K | - |
| Pretax Income | - | - | - | - | - | - | -1.74M | -2.50M | -3.26M | -4.41M | -2.73M |
| Tax Provision | - | - | - | - | - | 1.00K | - | 3.00K | 0 | 0 | - |
| Net Income | -1.88M | -809.00K | -1.42M | -1.49M | -11.86M | - | -1.74M | -2.50M | -3.26M | -4.41M | -2.73M |
| Diluted EPS | 6.54 | 0.78 | 12.29 | 197.80 | 274.25 | - | -39.00 | 43.20 | -28.80 | - | -8.50 |
| R&D Expense | 1.24M | 535.00K | 961.00K | 766.00K | 3.22M | - | 590.00K | 1.02M | 2.16M | - | 1.37M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 3.86M | 4.68M | 12.57M | 11.63M |
| Operating Income | -3.86M | -4.68M | -12.57M | -11.63M |
| EBITDA | -3.80M | -5.03M | -16.48M | -11.88M |
| Interest Expense | - | 6.00K | 7.00K | 13.00K |
| Pretax Income | -3.46M | -5.08M | -16.51M | -11.91M |
| Tax Provision | 24.00K | 32.00K | 10.00K | 3.00K |
| Net Income | -3.21M | -4.94M | -16.44M | -11.91M |
| Diluted EPS | -532.46 | -818.48 | -3,949.40 | -89.60 |
| R&D Expense | - | 3.71M | 5.82M | 7.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 9.33M | 5.26M | 2.86M | 7.21M |
| Current Assets | 8.84M | 4.98M | 2.25M | 6.64M |
| Cash & Equivalents | 8.26M | 4.59M | 1.19M | 5.99M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 16.41M | 17.31M | 6.85M | 4.61M |
| Current Liabilities | 1.61M | 2.20M | 3.52M | 2.76M |
| Long Term Debt | - | - | 2.96M | 1.57M |
| Total Debt | 271.00K | 171.00K | 4.49M | 2.04M |
| Total Equity | -10.66M | -15.48M | -3.99M | 2.60M |
| Shares Outstanding | 6.04K | 6.04K | 12.33K | 312.67K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -3.33M | -4.53M | -8.40M | -10.82M |
| Investing Cash Flow | -524.00K | 573.00K | -22.00K | -14.00K |
| Financing Cash Flow | 2.75M | 522.00K | 5.10M | 15.64M |
| Capital Expenditure | -40.00K | -12.00K | -22.00K | -9.00K |
| Free Cash Flow | -3.38M | -4.54M | -8.42M | -10.83M |
| Net Change in Cash | -1.11M | -3.43M | -3.31M | 4.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 30.1% | 31.9% | 412.2% | -457.6% |
| ROCE % | -50.0% | -153.0% | 1,904.7% | -261.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 0.26% | 15.24K | $6.64K |
| 2 | UBS Group AG | 0.02% | 1.41K | $614 |
| 3 | Montag A & Associates Inc | 0.01% | 300 | $130 |
| 4 | Pflug Koory, LLC | - | 33 | $14 |
| 5 | SBI Securities Co., Ltd. | - | 2 | $0 |
| 6 | Royal Bank of Canada | - | 76 | $33 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLXN
SLXN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1fQW9SMHNGeHgwc0hzOG0zRTZIVHc4Z2tCXzBYRU9rMkMwbFB6eVdXYjNmdzBETjlMV1FpTkgzb2VKTy1BUlVNYmUtRGVmMDVETWF6OER5b21NZ05KbTFrY0kyR3draVlyWkU4RmZuRWVKTnY1LVNfWjhn?oc=5" target="_blank">SLX…
SLXN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5fVVc2WHhDNHRUUmVUOTRmMG03bFFUTUNKT2dUQ3kzUlpzeGtwRDRwcDY3QTZoNFk0Tk9XNHJ0djdheDRwQVE?oc=5" target="_blank">SLXN</a> <font color="#6f6f6f">Finviz</font>…
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNHBjeHpYd2pETURtNVFLU1JMWksyLTVrbHhFczFiOVc4OTFVVWtYakZ3RXExUUlHeHRtck04aUF1bElxVVA2b2FCenMyUDJGZGFIYWxCYjNNbEhsTEhjc1RJLUFnME1qMlFpVDRCOERQYmJUVS0zcG4zNnROWE1NeG9rbmZBRFppeHd4U3…
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOc0pWeTZRVTNnNXhUWnVqZUhGX2lVeGdIREg4LVJiSnQ5cGNkUUZERG9YZkZhNzZLb1pQMUdMS1FPNzFkUjZYQ2NpR3BhdEJXOWVoWlAxLVFIUVQtNkhoQjJoTkNHYU5QYWZsaEU0cmZON3ZXUFdaZTFfWTJDTGZ5RGRFNE1YU3BCekJaUm…
Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPYXZiRGx4d21xVWtEYVZNbWdmanNEMjNHOEVFMk5hRHlKTUdNbVQxcmJHTmxkOVNkRldNUHZNRG9fQWl5RWRsQ05HTnN1ckVTdHpZS3RzUGRCMWNrSTkxcnFIdWFRNEd1VURtV3NlOGhISFFIOW0tX0cyTTl3TjBiY0FJdW9KV1pkRlhKYk…
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQRGhmRTFyNEFqalFNQlBaSGVIZmNQUk00cEtpbmZzOWd1ZXBVb3VDS3hrcGZENXI3Rlk4RWJqMGhyRW53ZWFydzZ1dnFvTXg2SFd4eWNqOFFwNUpUZ2h6SmZxZ0lJeFlmNkFIMXFGTnRtT01XOFJrNmxCSzBrMS1NU3FFM2dad09TT0RRbn…
SLXN — Frequently Asked Questions
What is the current share price of Silexion Therapeutics Corp (SLXN)?
As of 2026-09-19 21:16 PDT, Silexion Therapeutics Corp (SLXN) trades at $0.34 on NasdaqCM. Its 52-week range is $0.34 to $77.35.
What is the market capitalisation of SLXN?
Silexion Therapeutics Corp (SLXN) has a market capitalisation of $1.89M on NasdaqCM.
What is the P/E ratio of SLXN?
SLXN trades at a trailing price-to-earnings (P/E) ratio of -0.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 54.44.
Is SLXN a good stock to buy?
This page provides a data-driven analysis of Silexion Therapeutics Corp (SLXN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.